|
KMID : 1030220150160040252
|
|
Journal of Korean Diabetes
2015 Volume.16 No. 4 p.252 ~ p.259
|
|
|
Clinical Application of Glucagon-Like Peptide-1 Receptor Agonists
|
|
민세희:Min Se-Hee
조영민:Cho Young-Min
|
|
|
Abstract
|
|
|
|
Glucagon-like peptide 1 (GLP-1) is an incretin hormone that is released from enteroendocrine L-cells upon nutrient absorption; it stimulates glucose-dependent insulin secretion from pancreatic betacells. GLP-1 has pleiotropic effects including deceleration of gastric emptying, decreased appetite, and increased satiety. Treatment with GLP-1 receptor agonists (GLP-1RAs) improves glycemic control in patients with type 2 diabetes without increasing the risk of hypoglycemia or weight gain. Current GLP- 1RAs can be classified by their structure (exendin-4-based or human GLP-1-based), duration of action, and molecular size. Different GLP-1RAs exhibit different pharmacokinetics and pharmacodynamics. Herein we review the characteristics of available GLP-1RAs and discuss current issues such as insulin combination therapy and anti-obesity effects.
|
|
|
KEYWORD
|
|
|
Glucagon-like peptide 1, Obesity, Type 2 diabetes mellitus
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|